Thursday 15 October 2026
Export ELDN’s income statement to Excel — free account
Eledon Pharmaceuticals, Inc.
ELDN Healthcare Biotechnology
In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.
2.27
0.02
+0.89%
Follow ELDN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 117.61 | 61.56 | 27.36 | 7.20 | 4.50 | 3.81 | 2.03 | 1.07 | 1.52 | 1.35 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 1,425.60 | 181.44 | 154.98 | 93.78 | 27.32 | 22.91 | 5.14 | 3.70 | 5.54 | 4.98 | |||||
| People | |||||||||||||||
| People | Employees | 8 | 7 | 10 | 8 | 10 | 12 | 17 | 20 | 31 | 33 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (6) | (13) | (14) | (16) | (23) | (37) | (88) | (117) | (36) | (46) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (6) | (13) | (14) | (16) | (23) | (35) | (88) | (117) | (36) | (46) | |||||
| Depreciation | 0 | 0 | 0 | 2 | 0 | 0 | 49 | 0 | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (271.43) | (41.37) | (28.06) | (24.46) | (15.72) | (2.33) | (6.16) | (4.73) | (0.75) | (0.52) | |||||
| Cash flow | (231.13) | (57.44) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) | |||||
| Capex | 0.05 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (231.08) | (57.41) | (23.75) | (21.12) | (10.48) | (1.95) | (1.99) | (1.61) | (0.97) | (0.76) | |||||
| Book value | (126.85) | 74.79 | 28.94 | 14.43 | 131.35 | 11.07 | 5.89 | 0.29 | 2.43 | 1.67 | |||||
| Shares, m | 0 | 0 | 1 | 1 | 1 | 15 | 14 | 25 | 49 | 82 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (5) | (15) | (12) | (14) | (15) | (29) | (28) | (40) | (47) | (62) | ||||
| Capex | 0 | 0 | — | — | — | — | — | — | — | — | |||||
| Free cash flow | (5) | (15) | (12) | (14) | (15) | (29) | (28) | (40) | (47) | (62) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (3) | 18 | 12 | 9 | 113 | 84 | 53 | 52 | 132 | 117 | ||||
| Total debt | 3 | — | — | 0 | 0 | 1 | 1 | — | — | — | |||||
| Net debt | 2 | (17) | (13) | (9) | (114) | (85) | (56) | (51) | (140) | (133) | |||||
| Shareholders’ equity | (3) | 19 | 14 | 9 | 191 | 164 | 84 | 7 | 118 | 137 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (16.35) | (118.76) | (74.19) | (114.54) | (21.92) | (18.77) | (66.81) | (128.16) | (27.16) | (26.34) | ||||
| ROIC | 0.00 | (381.60) | (578.13) | (1,488.41) | (15.11) | (29.11) | (198.99) | 0.00 | 0.00 | (1,511.24) | |||||
| ROE | (19.17) | (156.79) | (82.87) | (133.66) | (22.80) | (19.46) | (70.89) | (652.92) | (518.40) | (63.56) | |||||
Negative figures in brackets.
Charts ten years each
Eledon Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PRQR ProQR Therapeutics N.V. | $196.1M | — (loss-making) | — (loss-making) | +135.03% (above 0%: growing) | n/m | −1.06% (below 0%: shrinking) | 100.00% | (100.72%) | Compare |
| LYEL Lyell Immunopharma, Inc. | $195.8M | — (loss-making) | — (loss-making) | −50.00% (below 0%: shrinking) | n/m | +1.31% (above 0%: growing) | 100.00% | (1,183,425.00%) | Compare |
| RNAC Cartesian Therapeutics, Inc. | $191.8M | — (loss-making) | — (loss-making) | −92.91% (below 0%: shrinking) | −7.84% (below 0%: shrinking) | −6.15% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ACOG Alpha Cognition Inc. | $191.7M | — (loss-making) | — | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| IVVD Invivyd, Inc. | $190.4M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $190.2M | — (loss-making) | — | — | n/m | −28.02% (below 0%: shrinking) | 0.00% | 0.00% | |
| CGEN Compugen Ltd. | $187.6M | 5.5× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| UPB Upstream Bio, Inc. | $187.3M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| SION Sionna Therapeutics, Inc. | $185.0M | — (loss-making) | — | — | n/m | −22.40% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $191.0M | — | — | +21.20% | — | −14.27% | 100.00% | (224.02%) |
Eledon Pharmaceuticals, Inc. (ELDN) key facts
- Eledon Pharmaceuticals, Inc. (ELDN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 15, 2026, ELDN traded at $2.27, a market capitalization of $190.2 million.
- Return on equity was −63.6% and debt-to-equity 0.00.
Eledon Pharmaceuticals, Inc. (ELDN) Latest News
No news at this impact. Lower the threshold for more.